Press Releases

January 06, 2022

Madison, WI [January 6, 2022] – FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cell (iPSC) technologies, and PhenoVista Biosciences (PhenoVista), a top provider of custom imaging-based phenotypic assay services, today announce a strategic alliance to improve the drug discovery process, by using iPSCs in screening. This alliance….

January 05, 2022

Melbourne, Australia [December 29, 2021] – Cynata Therapeutics Limited (ASX: “CYP” or “Cynata”), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce the execution of a Manufacturing Services Agreement (“MSA”) with FUJIFILM Cellular Dynamics, Inc (“FCDI”) for the manufacture and supply of Cynata’s Cymerus™ therapeutic mesenchymal stem cell (“MSC”) products derived from….

October 04, 2021

Tokyo, [September 30, 2021] – FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) has reached agreement on core terms with Australian regenerative medicine venture Cynata Therapeutics Limited (Cynata) to manufacture regenerative medicine products using induced pluripotent stem (iPS) cells. Based on the core terms, Fujifilm will conduct clinical and commercial manufacturing for Cynata’s pipeline….

May 17, 2021

Cambridge, Mass., and Madison, Wis. [May 17, 2021] – BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, FUJIFILM Cellular Dynamics, Inc. a leading global developer and manufacturer of human induced pluripotent stem (iPS) cell technologies, and Opsis Therapeutics, LLC, a joint venture of FUJIFILM Cellular Dynamics (FCDI) and David Gamm, M.D.,….

March 17, 2021

FUJIFILM Cellular Dynamics, Inc. and Sana Biotechnology, Inc. announced today that Sana has been granted a non-exclusive right to use FUJIFILM Cellular Dynamics’ iPSC platform for the development of commercial cell therapies.